Recent News for RGLS - Regulus Therapeutics Inc.

Date Title
Oct 16 Regulus Therapeutics Presents Preclinical Data Identifying RGLS4326 as a Potential Disease-Modifying Treatment for Autosomal Dominant Polycystic Kidney Disease at OTS Annual Meeting
Sep 20 Some Regulus Therapeutics (NASDAQ:RGLS) Shareholders Have Copped A 99% Share Price Wipe Out
Sep 12 Regulus Therapeutics Announces Publication in Nature Communications Identifying RGLS4326 as a Potential Promising Treatment for ADPKD
Sep 6 Benzinga's Top Upgrades, Downgrades For September 6, 2019
Sep 6 Cantor likes Durect in premarket analyst action
Sep 3 Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Aug 29 Regulus Therapeutics to Present at the Wells Fargo Healthcare Conference
Aug 8 Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates
Aug 8 Regulus Therapeutics EPS beats by $0.24, misses on revenue
Aug 8 Regulus Therapeutics Reports Second Quarter 2019 Financial Results and Recent Updates
Aug 6 What Percentage Of Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Do Insiders Own?
Aug 1 Will Regulus (RGLS) Report Negative Q2 Earnings? What You Should Know
Jul 30 Regulus Therapeutics Appoints Cris Calsada as Chief Financial Officer
Jul 25 The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug
Jul 25 35 Healthcare Stocks Moving In Wednesday's After-Market Session
Jul 24 HCSG, IRBT, SNAP and TER among midday movers
Jul 24 DelMar Pharmaceuticals leads healthcare gainers; Regulus Therapeutics leads the losers
Jul 24 CAT, SGEN, IRBT among premarket losers
Jul 24 FDA suspends enrollment in Phase 1 study of Regulus' RGLS4326; shares down 25% premarket
Jul 23 Regulus Therapeutics Announces RGLS4326 Program Update
Jun 11 Regulus Announces New Additions to Board of Directors
Jun 5 Regulus -4% on 27.8M-share offering by shareholders
May 20 S, TMUS among premarket gainers
May 14 Novavax leads healthcare gainers; Genetic Technologies and InspireMD among losers
May 10 The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales
Back to the Main RGLS Page...